Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT06411041

Effects of a Combined Program of Pelvic Floor Muscle Training and Yoga

This study aims to examine the effects of Pelvic Floor Muscle Training (PFMT) combined with yoga on relieving genitourinary symptoms, symptom-related quality of life, and improving sexual function in women with breast cancer. This study is a parallel randomized study with two groups. Women will be assigned to the experimental or control group by using the block randomization method. The experimental group will receive regular care and a 12-week program of PFMT and yoga. The control group will receive regular care. We collect relevant data from both groups at baseline and 4, 8, 12, and 24 weeks after baseline during the study period.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Conditions

Genitourinary Symptoms Quality of Life Sexual Function

Age range

20 year–60 year

Sex eligibility

Female

Study type

Interventional

Phase

Not applicable

Primary location

MacKay Memorial Hospital

Taipei, 10449, Taiwan

About this study

This study will be conducted with the approval obtained from the Institutional Review Board (IRB) of MacKay Memorial Hospital. This parallel-two-group randomized experimental study including an experimental group and a control group examines the effects of pelvic floor muscle training (PFMT) combined with yoga on genitourinary symptoms, symptom-related quality of life, and sexual function. A sample of women with breast cancer experiencing ≥1 genitourinary symptom(s) will be recruited and assigned to an experimental group or a control group by using the block randomization method. The experimental group will receive regular care and a 12-week program of PFMT and yoga. We will provide the experimental group with 12 days of online group practice sections of PFMT and yoga (weekly 60-minute practice incudes yoga 40 minutes, PFMT 15 minutes, and reflection 5 minutes). We expect them to perform 36 days of home-based practice of PFMT and yoga with 3 days/week of yoga for 40 minutes and PFMT for 15 minutes. The control group will receive regular care and relevant educational materials after data collection. Information will be collected at five time points: baseline and 4, 8, 12, and 24 weeks after baseline. Generalized estimating equation procedures will be used to examine the effects of the intervention. We hypothesized that the experimental group will display more significant improvements in genitourinary symptoms, symptom-related influences, and sexual function than those shown in the control group.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Women aged 20-60 years
  • Women with a confirmed diagnosis of breast cancer (Stages I-III) for ≥3 months
  • Women who experience ≥1 genitourinary symptom(s)

Exclusion criteria

  • Women with other types of cancer diagnoses (e.g., endometrial cancer and ovarian cancer)
  • Women with inadequately managed chronic conditions (e.g., an individual with diabetes having HbA1c level >7%)

Treatment and study plan

Pelvic Floor Muscle Training (PFMT) and yoga

Behavioral

The experimental group participants will be instructed to perform the practice session four days a week. The four days per week practice times (PFMT 15 minutes/day; yoga 40 minutes/day.) will result in weekly practice times for pelvic floor muscle training (PFMT) of 60 minutes and for yoga of ≥150 minutes.

Primary outcomes

  1. Vulvovaginal Symptoms

    Time frame: Baseline

    The 21-item Chinese version of the Vulvovaginal Symptoms Questionnaire (C-VSQ) comprises four subscales to assess vulvovaginal symptoms experienced during the past week (Items 1-7), and symptom-related influences (Emotions Items 8-11; Life-impact Items 12-15, and Sexual-impact Items 16, 18-21). The response options for all items are "Yes" (1 point) and "No" (0 point). Subscale scores are the sum of the scores for the items included in that subscale. The C-VSQ total score is the sum of three subscale scores (0-15 points) or four subscale scores (0-20 points for sexually active women). A higher C-VSQ total score indicates experiencing greater severity of vulvovaginal symptoms and symptom-related influences.

  2. Vulvovaginal Symptoms

    Time frame: 4 weeks after baseline

    The 21-item Chinese version of the Vulvovaginal Symptoms Questionnaire (C-VSQ) comprises four subscales to assess vulvovaginal symptoms experienced during the past week (Items 1-7), and symptom-related influences (Emotions Items 8-11; Life-impact Items 12-15, and Sexual-impact Items 16, 18-21). The response options for all items are "Yes" (1 point) and "No" (0 point). Subscale scores are the sum of the scores for the items included in that subscale. The C-VSQ total score is the sum of three subscale scores (0-15 points) or four subscale scores (0-20 points for sexually active women). A higher C-VSQ total score indicates experiencing greater severity of vulvovaginal symptoms and symptom-related influences.

  3. Vulvovaginal Symptoms

    Time frame: 8 weeks after baseline

    The 21-item Chinese version of the Vulvovaginal Symptoms Questionnaire (C-VSQ) comprises four subscales to assess vulvovaginal symptoms experienced during the past week (Items 1-7), and symptom-related influences (Emotions Items 8-11; Life-impact Items 12-15, and Sexual-impact Items 16, 18-21). The response options for all items are "Yes" (1 point) and "No" (0 point). Subscale scores are the sum of the scores for the items included in that subscale. The C-VSQ total score is the sum of three subscale scores (0-15 points) or four subscale scores (0-20 points for sexually active women). A higher C-VSQ total score indicates experiencing greater severity of vulvovaginal symptoms and symptom-related influences.

  4. Vulvovaginal Symptoms

    Time frame: 12 weeks after baseline

    The 21-item Chinese version of the Vulvovaginal Symptoms Questionnaire (C-VSQ) comprises four subscales to assess vulvovaginal symptoms experienced during the past week (Items 1-7), and symptom-related influences (Emotions Items 8-11; Life-impact Items 12-15, and Sexual-impact Items 16, 18-21). The response options for all items are "Yes" (1 point) and "No" (0 point). Subscale scores are the sum of the scores for the items included in that subscale. The C-VSQ total score is the sum of three subscale scores (0-15 points) or four subscale scores (0-20 points for sexually active women). A higher C-VSQ total score indicates experiencing greater severity of vulvovaginal symptoms and symptom-related influences.

  5. Vulvovaginal Symptoms

    Time frame: 24 weeks after baseline

    The 21-item Chinese version of the Vulvovaginal Symptoms Questionnaire (C-VSQ) comprises four subscales to assess vulvovaginal symptoms experienced during the past week (Items 1-7), and symptom-related influences (Emotions Items 8-11; Life-impact Items 12-15, and Sexual-impact Items 16, 18-21). The response options for all items are "Yes" (1 point) and "No" (0 point). Subscale scores are the sum of the scores for the items included in that subscale. The C-VSQ total score is the sum of three subscale scores (0-15 points) or four subscale scores (0-20 points for sexually active women). A higher C-VSQ total score indicates experiencing greater severity of vulvovaginal symptoms and symptom-related influences.

Secondary outcomes

  1. Urinary symptoms

    Time frame: Baseline

    We investigated eight common urinary symptoms using the lower urinary tract symptoms (LUTS) subscale. The LUTS subscale investigates (a) urinary incontinence, (b) increased daytime urinary frequency, (c) urgency, (d) nocturia, (e) intermittent stream/intermittency, (f) slow stream, (g) hesitancy, and (h) a feeling of incomplete emptying. A higher total LUTS score (Range 0-11) indicates that a woman experiences a greater number of different types of urinary symptoms.

  2. Urinary symptoms

    Time frame: 4 weeks after baseline

    We investigated eight common urinary symptoms using the lower urinary tract symptoms (LUTS) subscale. The LUTS subscale investigates (a) urinary incontinence, (b) increased daytime urinary frequency, (c) urgency, (d) nocturia, (e) intermittent stream/intermittency, (f) slow stream, (g) hesitancy, and (h) a feeling of incomplete emptying. A higher total LUTS score (Range 0-11) indicates that a woman experiences a greater number of different types of urinary symptoms.

  3. Urinary symptoms

    Time frame: 8 weeks after baseline

    We investigated eight common urinary symptoms using the lower urinary tract symptoms (LUTS) subscale. The LUTS subscale investigates (a) urinary incontinence, (b) increased daytime urinary frequency, (c) urgency, (d) nocturia, (e) intermittent stream/intermittency, (f) slow stream, (g) hesitancy, and (h) a feeling of incomplete emptying. A higher total LUTS score (Range 0-11) indicates that a woman experiences a greater number of different types of urinary symptoms.

  4. Urinary symptoms

    Time frame: 12 weeks after baseline

    We investigated eight common urinary symptoms using the lower urinary tract symptoms (LUTS) subscale. The LUTS subscale investigates (a) urinary incontinence, (b) increased daytime urinary frequency, (c) urgency, (d) nocturia, (e) intermittent stream/intermittency, (f) slow stream, (g) hesitancy, and (h) a feeling of incomplete emptying. A higher total LUTS score (Range 0-11) indicates that a woman experiences a greater number of different types of urinary symptoms.

  5. Urinary symptoms

    Time frame: 24 weeks after baseline

    We investigated eight common urinary symptoms using the lower urinary tract symptoms (LUTS) subscale. The LUTS subscale investigates (a) urinary incontinence, (b) increased daytime urinary frequency, (c) urgency, (d) nocturia, (e) intermittent stream/intermittency, (f) slow stream, (g) hesitancy, and (h) a feeling of incomplete emptying. A higher total LUTS score (Range 0-11) indicates that a woman experiences a greater number of different types of urinary symptoms.

Other outcomes

  1. Sexual function

    Time frame: Baseline

    The 19-item Female Sexual Function Index (FSFI) consists of six domains: sexual desire (Items 1-2), subjective arousal (Items 3-6), lubrication (Items 7-10), orgasm (Items 11-13), satisfaction (Items 14-16), and pain (Items 17-19). The total score is the sum of all the item scores. A higher FSFI total score indicates better overall sexual functioning.

  2. Sexual function

    Time frame: 4 weeks after baseline

    The 19-item Female Sexual Function Index (FSFI) consists of six domains: sexual desire (Items 1-2), subjective arousal (Items 3-6), lubrication (Items 7-10), orgasm (Items 11-13), satisfaction (Items 14-16), and pain (Items 17-19). The total score is the sum of all the item scores. A higher FSFI total score indicates better overall sexual functioning.

  3. Sexual function

    Time frame: 8 weeks after baseline

    The 19-item Female Sexual Function Index (FSFI) consists of six domains: sexual desire (Items 1-2), subjective arousal (Items 3-6), lubrication (Items 7-10), orgasm (Items 11-13), satisfaction (Items 14-16), and pain (Items 17-19). The total score is the sum of all the item scores. A higher FSFI total score indicates better overall sexual functioning.

  4. Sexual function

    Time frame: 12 weeks after baseline

    The 19-item Female Sexual Function Index (FSFI) consists of six domains: sexual desire (Items 1-2), subjective arousal (Items 3-6), lubrication (Items 7-10), orgasm (Items 11-13), satisfaction (Items 14-16), and pain (Items 17-19). The total score is the sum of all the item scores. A higher FSFI total score indicates better overall sexual functioning.

  5. Sexual function

    Time frame: 24 weeks after baseline

    The 19-item Female Sexual Function Index (FSFI) consists of six domains: sexual desire (Items 1-2), subjective arousal (Items 3-6), lubrication (Items 7-10), orgasm (Items 11-13), satisfaction (Items 14-16), and pain (Items 17-19). The total score is the sum of all the item scores. A higher FSFI total score indicates better overall sexual functioning.

  6. Quality of life and distress associated with pelvic floor symptoms

    Time frame: Baseline

    The 20-item Pelvic Floor Distress Inventory-20 (PFDI-20) consists of three sections: Pelvic Organ Prolapse Distress Inventory 6 (POPDI-6; Items 1-6), Colorectal-Anal Distress Inventory (CRAD-8; Items 7-14), and Urinary Distress Inventory 6 (UDI-6; Items 15-20). The total score ranges from 0-300, and a higher PFDI-20 total score indicates more severe influences associated with pelvic floor symptoms.

  7. Quality of life and distress associated with pelvic floor symptoms

    Time frame: 4 weeks after baseline

    The 20-item Pelvic Floor Distress Inventory-20 (PFDI-20) consists of three sections: Pelvic Organ Prolapse Distress Inventory 6 (POPDI-6; Items 1-6), Colorectal-Anal Distress Inventory (CRAD-8; Items 7-14), and Urinary Distress Inventory 6 (UDI-6; Items 15-20). The total score ranges from 0-300, and a higher PFDI-20 total score indicates more severe influences associated with pelvic floor symptoms.

  8. Quality of life and distress associated with pelvic floor symptoms

    Time frame: 8 weeks after baseline

    The 20-item Pelvic Floor Distress Inventory-20 (PFDI-20) consists of three sections: Pelvic Organ Prolapse Distress Inventory 6 (POPDI-6; Items 1-6), Colorectal-Anal Distress Inventory (CRAD-8; Items 7-14), and Urinary Distress Inventory 6 (UDI-6; Items 15-20). The total score ranges from 0-300, and a higher PFDI-20 total score indicates more severe influences associated with pelvic floor symptoms.

  9. Quality of life and distress associated with pelvic floor symptoms

    Time frame: 12 weeks after baseline

    The 20-item Pelvic Floor Distress Inventory-20 (PFDI-20) consists of three sections: Pelvic Organ Prolapse Distress Inventory 6 (POPDI-6; Items 1-6), Colorectal-Anal Distress Inventory (CRAD-8; Items 7-14), and Urinary Distress Inventory 6 (UDI-6; Items 15-20). The total score ranges from 0-300, and a higher PFDI-20 total score indicates more severe influences associated with pelvic floor symptoms.

  10. Quality of life and distress associated with pelvic floor symptoms

    Time frame: 24 weeks after baseline

    The 20-item Pelvic Floor Distress Inventory-20 (PFDI-20) consists of three sections: Pelvic Organ Prolapse Distress Inventory 6 (POPDI-6; Items 1-6), Colorectal-Anal Distress Inventory (CRAD-8; Items 7-14), and Urinary Distress Inventory 6 (UDI-6; Items 15-20). The total score ranges from 0-300, and a higher PFDI-20 total score indicates more severe influences associated with pelvic floor symptoms.

Sponsors and collaborators

Lead sponsor

National Yang Ming Chiao Tung University

Other

Registry information

Official study title

Effects of a Combined Program of Pelvic Floor Muscle Training and Yoga on Relieving Genitourinary Symptoms, and Improving Sexual Function and Quality of Life in Asian Women With Breast Cancer

Important dates

Study start
2024
Primary completion
2025
Study completion
2027
First posted
May 13, 2024
Registry last updated
Nov 21, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.